Cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2024, were $267.1 million, compared to cash, cash equivalents, restricted cash, and marketable securities of $197.8 million as of March 31, 2024. The Company expects its cash and cash equivalents to be sufficient to fund planned operations and capital expenditures into the first half of 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
- These 2 ‘Strong Buy’ Penny Stocks Could Jump at Least 300%, Says Piper Sandler
- Monte Rosa Therapeutics Reports Progress on Drug Development
- Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Questions or Comments about the article? Write to editor@tipranks.com